Skip to Main Content
Important information:
Important Information Regarding Medicare Advantage Plans – Learn More.
  • Sylvester Comprehensive Cancer Center |
  • Bascom Palmer Eye Institute
University of Miami Health
  • Appointments
  • Pay a Bill
  • Refer a Patient
  • International Patients
  • Donate Now
  • Search
  • Patient Login
  • Find a Doctor
  • Treatments Page 1
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
    Browse A-Z A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Featured Treatments For
    • Allergy and Immunology
    • Arthritis (Rheumatology)
    • Bariatrics (Weight Loss Surgery)
    • Cancer (Oncology)
    • Cardiac and Vascular
    • Concierge Medicine
    • Dentistry
    • Dermatology
    • Diabetes
    • Ear, Nose, and Throat (ENT)
    • Emergency Care
    • Endocrinology, Diabetes and Metabolism
    • Executive Physicals
    • Eye Care (Ophthalmology)
    • Fertility Center
    • Gastrointestinal
    • Genetics
    • Geriatrics
    • Hepatology
    • High Blood Pressure (Hypertension)
    • Hyperbaric Oxygen Therapy
    • Infectious Diseases
    • Internal Medicine
    • Interventional Radiology
    • Lymphedema
    • Nephrology
    • Neurology
    • Neurosurgery
    • Obstetrics and Gynecology
    • Orthopaedics
    • Pain Management and Palliative Care
    • Pediatrics
    • Physical Medicine and Rehabilitation
    • Plastic Surgery
    • Primary Care
    • Psychiatry
    • Pulmonary Medicine
    • Radiology
    • Sleep Medicine
    • Sports Medicine Institute
    • Surgery
    • Transplant
    • UHealth Comprehensive Women’s Health Alliance
    • UHealth Premier
    • Urology
    View all Treatments
  • Locations
  • Patients & Families
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
    Traveling from overseas?
    We can help plan your visit. Learn More
    Quick links
    • Appointments
    • Pay a Bill
    • Make a Gift
    • Insurance Plans Accepted
    • MyUHealthChart
    • Advance Directives
    For Patients & Families
    • Your First Visit
    • Medical Records
    • Frequently Asked Questions
    • Patient and Caregiver Resources
    • Patients & Families
    • Public Transportation
    • UHealth Clinic at Walgreens
    • Classes & Events
    • Support Groups
    • Interpreter Services
    • International Patients
    • UMiami Health Talks
    About Uhealth
    • Why Choose UHealth
    • Benefits of an Academic Medical Center
    • Mission & Values
    • Leadership
    • Community Health Improvement
    • Nursing at UHealth
    • Health News
    • Miller School of Medicine
    • University of Miami
    • Careers
    • Volunteers
    • Contact Us
    Clinical Trials
    • Find a Clinical Trial
    • Understanding Clinical Trials
    • Clinical Trials FAQ's
Patient Login
  • University of Miami Health System
  • Clinical Trials
  • This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Principal Investigator

Philip Harvey

Enrollment Status

Closed

Clinical Trial ID

Institutional Protocol # 20190214
National Clinical Trials Identifier NCT03859973

Clinical Trial Summary

This is a study in adults with schizophrenia. The study tests whether a medicine called BI
425809 together with brain training improves mental abilities.
Participants take study medication once a day for 12 weeks. At the start of the study, the
participants are put into 2 groups. It is decided by chance who gets into which group. One
group gets BI 425809 tablets every day. The other group gets placebo tablets every day.
Placebo tablets look like the BI 425809 tablets, but contain no medicine. During the study,
all participants do brain training using a computer.
The doctors regularly test mental abilities of the participants. The results of the mental
ability tests are compared between the groups. The doctors also check the general health of
the patients.


Phase

Phase 2


Funding Agency/Sponsor

Industry


Disease

Other


Enrollment Eligibility

Inclusion Criteria:
- Signed and dated written informed consent in accordance with ICH Harmonized Tripartite
Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to
admission to the trial.
- Male or female patients who are 18-50 years (inclusive) of age at time of consent.
- Established schizophrenia (as per DSM-5) with the following clinical features:
- Outpatient, with no hospitalization for worsening of schizophrenia within 3
months prior to randomization
- Psychiatrically stable without symptom exacerbation within 3 months prior to
randomization
- PANSS score ≤ 5 on positive items P1, P3-P7 and ≤ 4 on positive item P2 at Visit
1, and confirmed at Visit 2
- Patients must be on stable antipsychotic treatment; also, current antipsychotic
medications and concomitant anticholinergics, antiepileptics, lithium and allowed
antidepressants must meet the criteria below:
- Patients must take 1 and may take up to 2 antipsychotics (typical and/or
atypical), except for clozapine
- Patients must be stable on current antipsychotics, anticholinergics,
antiepileptics, lithium and allowed antidepressants for at least 3 months prior
to randomization and be on current dose for at least 30 days prior to
randomization o Patients on Long-Acting Injectable (LAI) antipsychotics should be
on the same medication and dose for at least 3 months prior to randomization
- Women of childbearing potential (WOCBP)2 must be ready and able to use highly
effective methods of birth control per Non-Clinical Safety Studies for the Conduct of
Human Clinical Trials and Marketing Authorization for Pharmaceuticals (ICH M3 (R2))
that result in a low failure rate of less than 1% per year when used consistently and
correctly. A list of contraception methods meeting these criteria is provided in
Section 4.2.2.3. Such methods should be used throughout the trial, and for a period of
at least 35 days after last trial drug intake, and the patient must agree to periodic
pregnancy testing during participation in the trial.
- Patients must demonstrate their ability to properly use the CCT device and program, as
well as be compliant with CCT run-in (defined as completing at least 2 hours per week
for two weeks, totalling 4 hours CCT, during the screening period)3.
- Patients must be able to comply with all protocol procedures, in the investigator's
opinion.
- Patients must have a study partner who will preferably be consistent throughout the
study. It is recommended that the study partner should interact (in-person or
telephone) with the subject at least 2 times a week.
Exclusion Criteria:
- Patients who have a categorical diagnosis of another current major psychiatric
disorder on the Mini-International Neuropsychiatric Interview (M.I.N.I.).
- Diseases of the central nervous system (CNS) that may impact the assessment of the
cognitive tests as per investigator's opinion. A movement disorder due to
antipsychotic treatment not currently controlled with anti- EPS treatment or another
movement disorder (e.g. Parkinson´s disease).
- Patients with a history of participating in any formal cognitive remediation program
for 10 or more training sessions.
- Patients who were treated with any of the following medications within the last 6
months prior to randomization:
- Bitopertin, BI 409306, encenicline or other investigational drug testing effects
on cognition in schizophrenia
- Clozapine (atypical antipsychotic medication)
- Sarcosine, cycloserine, serine and glycine
- Stimulants (e.g. methylphenidate, dextroamphetamine, modafinil)
- Tricyclic antidepressants
- Patients receiving any other investigational drug (other than a potential cognitive
enhancing drug) within 30 days or 6 half-lives (whichever is longer) prior to
randomization. For investigational LAI antipsychotics, the last injection must be at
least 3 months or two administration cycles (i.e. 6 months if administration is every
3 months) prior to randomization, whichever is longer.
- Patients who have participated in a clinical trial with repeated assessments (i.e. a
single assessment is not exclusionary) with the MATRICS Consensus Cognitive Battery
(MCCB) within the last 6 months prior to randomization.
- Patients who required a change in ongoing benzodiazepine or sleep medication dose or
regimen within the last 30 days prior to randomization.
- Patients with known active infection with SARS-CoV-2 within the last 30 days prior to
randomization.
- Other exclusion criteria apply


Contact Information

Study Contact Mary Gorora
Phone Number +1 (305) 2437276
Email meg82337@miami.edu
Get detailed information on ClinicalTrials.Gov

logo
alt="Twitter Logo">
USNWR Best Hospitals 2026-2027 USNWR Best Regional Hospitals 2026-2027
Quick links
  • Appointments
  • Find a Doctor
  • Pay a Bill
  • Insurance Plans Accepted
  • MyUHealthChart
  • Make a Gift
Patient & Families
  • Frequently Asked Questions
  • Medical Records
  • Interpreter Services
  • Clinical Trials
  • International Patients
  • UHealth Clinic at Walgreens
  • Support Groups
  • Price Transparency
  • Florida Health Finder
Healthcare Professionals
  • Refer a Patient
  • Physician & Executive Recruitment
  • Advanced Practice Providers
  • Immunology & Histocompatibility Laboratory
  • Nursing
  • Sleep Center
  • Sports Medicine Institute
  • Pathology Reference Services
About Uhealth
  • Why Choose UHealth
  • Benefits of an Academic Medical Center
  • Mission & Values
  • Leadership
  • Facts & Figures
  • Community Health Improvement
  • For Media
  • Miller School of Medicine
  • University of Miami
  • Careers
  • Volunteers
  • Supply Chain
  • Contact Us

Medical Disclaimer | Terms of Use | Privacy Statement | HIPAA Notice of Privacy Practices | Non-Discrimination Policy | No Surprises Billing Rights
© 2026 University of Miami Health System. All rights reserved.